Tevogen Bio Holdings Inc.
TVGNNasdaq
$4.21
↓ -4.5%Jul 17 close · end-of-day
Price
1Y↓ -93.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$14.7M
Enterprise Value
$14.7M
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$21.4M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
217.0%
ROIC
—
Debt / Equity
—
Net Cash
—
Return 1Y
-93.2%
Company profile
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company was founded in 2020 and is based in Warren, New Jersey.
- CEO
- Ryan Saadi
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 3
- Headquarters
- New Jersey
- Website
- tevogen.com
Management & directors
- Desai KirtiChief Financial Officer
- Saadi Ryan H.Chief Executive Officer
- Flomenberg NealSee Remarks
- Khan SadiqChief Commercial Officer
Roles derived from SEC Form 4 filings.
Earnings
TVGN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$1.61↓ -50.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | -$8.8M | -$53.6M | -$26.1M |
| Net income | $4.4M | -$60.5M | -$13.7M | -$26.3M |
| Diluted EPS | — | -$2.44 | -$3.50 | -$8.08 |
| Operating cash flow | -$215,395.00 | -$8.2M | -$12.0M | -$12.3M |
| Free cash flow | — | -$8.3M | — | -$12.4M |
| Gross margin | — | — | — | — |
| Operating margin | — | — | — | — |
| Net margin | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$8.6M | -$6.1M | -$9.4M | -$10.4M | -$5.4M | -$5.7M | -$4.6M | -$5.4M |
| Net income | -$9.7M | -$5.9M | -$9.4M | -$10.4M | -$5.5M | -$5.7M | -$4.7M | -$5.4M |
| Diluted EPS | -$0.04 | -$0.03 | -$3.17 | -$3.25 | -$0.03 | -$0.03 | -$4.77 | -$1.61 |
| Operating cash flow | -$3.0M | -$3.8M | -$3.0M | -$3.3M | -$3.2M | -$3.6M | -$2.2M | -$2.7M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-10 | Sordillo Victor J. | Award | 40,000 | $0.00 | $0.00 | filing |
| 2026-07-10 | Saadi Ryan H.· Chief Executive Officer | Award | 1,220,000 | $0.00 | $0.00 | filing |
| 2026-07-10 | PODLOGAR SUSAN M | Award | 40,000 | $0.00 | $0.00 | filing |
| 2026-07-10 | Patton Curtis L. | Award | 40,000 | $0.00 | $0.00 | filing |
| 2026-07-10 | Goh Keow Lin | Award | 40,000 | $0.00 | $0.00 | filing |
| 2026-07-10 | Feike Jeffrey L. | Award | 40,000 | $0.00 | $0.00 | filing |
| 2026-07-10 | Desai Kirti· Chief Financial Officer | Award | 40,000 | $0.00 | $0.00 | filing |
| 2026-03-13 | Flomenberg Neal· See Remarks | Sale | 501 | $6.40 | $3,206.40 | filing |
| 2026-03-11 | Flomenberg Neal· See Remarks | Sale | 452 | $7.26 | $3,281.52 | filing |
| 2026-03-10 | Flomenberg Neal· See Remarks | Sale | 19 | $7.75 | $147.25 | filing |
| 2025-12-18 | Saadi Ryan H.· Chief Executive Officer | Gift | 50,000 | $0.00 | $0.00 | filing |
| 2025-12-11 | Desai Kirti· Chief Financial Officer | Gift | 300,000 | $0.00 | $0.00 | filing |
| 2025-12-11 | Saadi Ryan H.· Chief Executive Officer | Gift | 460,000 | $0.00 | $0.00 | filing |
| 2025-08-15 | Saadi Ryan H.· Chief Executive Officer | Gift | 20,000 | $0.00 | $0.00 | filing |
| 2025-06-27 | Saadi Ryan H.· Chief Executive Officer | Award | 8,000,000 | $0.00 | $0.00 | filing |
| 2025-06-27 | Khan Sadiq· Chief Commercial Officer | Award | 200,000 | $0.00 | $0.00 | filing |
| 2025-06-27 | Flomenberg Neal· See Remarks | Award | 300,000 | $0.00 | $0.00 | filing |
| 2025-06-27 | Desai Kirti· Chief Financial Officer | Award | 750,000 | $0.00 | $0.00 | filing |
Latest 18 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.